Antisense Receives Approval to Conduct Phase IIb Trial of ATL1102 and Appoints New CEO

May 23, 2023

On May 23, 2023, Antisense Therapeutics announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy in Bulgaria. They also announced the appointment of their new CEO, Dr. James Garner, MBBS, MBA.

To read their ATL1102 trial press release, please click here.

To read their press release announcing the appointment of their CEO, please click here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open